OTCMKTS:USRM - US Stem Cell Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0220 0.00 (0.00 %)
(As of 11/15/2018 11:32 AM ET)
Previous Close$0.0220
Today's Range$0.0216 - $0.0221
52-Week Range$0.02 - $0.0880
Volume115,985 shs
Average Volume2.20 million shs
Market Capitalization$9.36 million
P/E RatioN/A
Dividend YieldN/A
Beta6.22
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training services, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

Receive USRM News and Ratings via Email

Sign-up to receive the latest news and ratings for USRM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:USRM
Previous SymbolNASDAQ:BHRT
CUSIPN/A
Phone954-835-1500

Debt

Debt-to-Equity RatioN/A
Current Ratio0.26
Quick Ratio0.24

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.52 million
Price / Sales1.49
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-1.10

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-3,480,000.00
Net Margins-21.01%
Return on EquityN/A
Return on Assets-66.41%

Miscellaneous

Employees11
Outstanding Shares374,580,000
Market Cap$9.36 million
OptionableNot Optionable

US Stem Cell (OTCMKTS:USRM) Frequently Asked Questions

What is US Stem Cell's stock symbol?

US Stem Cell trades on the OTCMKTS under the ticker symbol "USRM."

How were US Stem Cell's earnings last quarter?

US Stem Cell Inc (OTCMKTS:USRM) posted its quarterly earnings results on Wednesday, August, 8th. The company reported $0.00 earnings per share (EPS) for the quarter. The company earned $1.82 million during the quarter. View US Stem Cell's Earnings History.

When is US Stem Cell's next earnings date?

US Stem Cell is scheduled to release their next quarterly earnings announcement on Monday, April 15th 2019. View Earnings Estimates for US Stem Cell.

Has US Stem Cell been receiving favorable news coverage?

News stories about USRM stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. US Stem Cell earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of US Stem Cell's key competitors?

Who are US Stem Cell's key executives?

US Stem Cell's management team includes the folowing people:
  • Mr. Michael Tomas, CEO, Pres, CFO & Director (Age 52)
  • Dr. Kristin C. Comella Ph.D., Chief Science Officer & Director (Age 41)
  • Dr. Colleen Robb, Sr. Compliance Officer
  • Mr. Phil Posa, Sr. VP of U.S. & International Sales
  • Ms. Evelyn Flores, Corp. Controller

How do I buy shares of US Stem Cell?

Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is US Stem Cell's stock price today?

One share of USRM stock can currently be purchased for approximately $0.0220.

How big of a company is US Stem Cell?

US Stem Cell has a market capitalization of $9.36 million and generates $5.52 million in revenue each year. US Stem Cell employs 11 workers across the globe.

What is US Stem Cell's official website?

The official website for US Stem Cell is http://www.us-stemcell.com.

How can I contact US Stem Cell?

US Stem Cell's mailing address is 13794 NW 4TH STREET SUITE 212, SUNRISE FL, 33325. The company can be reached via phone at 954-835-1500 or via email at [email protected]


MarketBeat Community Rating for US Stem Cell (OTCMKTS USRM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about US Stem Cell and other stocks. Vote "Outperform" if you believe USRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe USRM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2018 by MarketBeat.com Staff

Featured Article: What is the S&P 500 Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel